BenevolentAI - Using AI to Disrupt Traditional Drug Discovery Process
|
Case Code: BSTR569 Case Length: 10 Pages Period: 2013-2018 Pub Date: 2019 Teaching Note: Available |
Price: Rs.300 Organization: BenevolentAI Industry: Pharmaceutical Countries: United Kingdom Themes: Disruptive Innovation, Incremental Innovation, Strategic Innovation, Breakthrough Innovation, Traditional Drug Discovery Process |
Abstract Case Intro 1 Case Intro 2 Excerpts
Company Background
BAI was founded by Ken Mulvany (Mulvany), Brent Gutekunst (Gutekunst), Michael Brennan (Brennan), and Ivan Griffin (Griffin) in 2013 in the UK. The company had its headquarters in the UK with offices in Belgium and New York. In 2014, the company received funding of US$ 87.70 million from Woodford Investment Management LLP and other private investors. In April 2017, BAI entered into a two-year agreement with MRCT to collaborate in drug discovery in the areas of antibodies and small molecules. In 2017, BAI stated that it had made a positive breakthrough in ALS and had entered into license agreements with top pharmaceutical companies to conduct the first Phase IIb clinical study...
Buy this case study (Please select any one of the payment options)
| Price: Rs.300 |
Price: Rs.300 | PayPal (7 USD) |
